▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3577 by analyst upside · 2026-06-27
ABBV
AbbVie Inc.
Healthcare · Market Cap $448B · P/E 118.9x
ANALYST PRICE TARGET
+0.4%
implied upside to consensus target
Current Price $253.35
Consensus Target $254.38
Bull Target $328.0
Bear Target $200.0
Analysts Covering 29
ANALYST CONSENSUS — BUY
Strong Buy
7
Buy
13
Hold
8
Sell
1
52-Week Low $181.73
52-Week High $253.35
YTD Return +12.3%
FUNDAMENTALS
Market Cap $448B
P/E Ratio (TTM) 118.9x
Forward P/E 15.6x
EPS (TTM) $2.13
PEG Ratio 0.65
Dividend Yield 2.73%
Revenue (TTM) $62.8B
Profit Margin 5.8%
52-WEEK RANGE
52-Week Low $181.73
52-Week High $253.35
Current Price $253.35
Bear Target $200.0
Bull Target $328.0
● Now $253.35 ● Target $254.38
TRADING DATA
Avg Volume 6.3M
YTD Return +12.3%
Analyst Count 29
Consensus Buy
Upside to Target +0.4%
Last Updated 2026-06-27

ANALYST SUMMARY

AbbVie Inc. (ABBV) is currently trading at $253.35 with a Wall Street consensus price target of $254.38, implying potential upside of 0.4% over the next 12 months. 29 analysts currently cover ABBV, with a consensus rating of Buy — 69% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $328.0, while the most cautious has a target of $200.0.

ABBV operates in the Healthcare sector with a market capitalisation of $448B. The stock is up 12.3% year-to-date and is currently trading near the upper end of its 52-week range of $181.73 – $253.35.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UNH -3.9%
UnitedHealth Group Incorporated
$389B · P/E 32.2x · Buy
MRK +1.3%
Merck & Co., Inc.
$318B · P/E 35.3x · Buy
JNJ +1.0%
Johnson & Johnson
$613B · P/E 29.5x · Buy
AZN +19.1%
AstraZeneca PLC
$292B · P/E 27.9x · Buy
NVS -1.0%
Novartis AG
$297B · P/E 22.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ABBV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group — Reiterated
Outperform → Outperform 2026-05-15 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-14 14% win rate (7 calls)
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-05-04 Building track record
Guggenheim reit
Buy → Buy 2026-05-01 62% win rate (8 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-04-30 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-04-30 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-04-30 40% win rate (10 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2026-04-23 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →